GP Extended Action Triptorelin

Stopped The study was discontinued prematurely by the sponsor due to non-medical reasons

Conditions

• Prostate Cancer

Interventions

• DRUG: Decapeptyl® SR 22.5mg
• DRUG: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg

Sponsor

Ipsen